Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males/females aged ≥ 21 years and ≤ 65 years~* Diagnosis of Type 2 Diabetes for ≤ 20 years~* Obese individuals (BMI ≥ 30 kg/m2 and ≤ 55 kg/m2)~* Stable doses (at least 3 months) of up to two anti-T2DM medications (MET, SU, DPP-4i or TZD)~* Glycemic state: HbA1c at screening ≥ 7.5% and ≤ 10.0%.~* Subjects willing to comply with study requirements~* Subjects who have signed an informed consent form~Exclusion Criteria:~* Diagnosis of type 1 diabetes mellitus or having any history of ketoacidosis~* C-peptide \< 1.0 ng/mL~* Triglyceride level \> 400 mg/dL~* Vitamin D deficiency (\<20 ng/mL)~* Male subjects with serum Creatinine \>1.5 mg/dl or female subjects with Creatinine \>1.4 mg/dL~* Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/microliter, or known coagulopathy~* Height \< 5 feet (152.4 cm)~* Current alcohol or drug addiction~* Symptomatic kidney stones or gallstones within 6 months prior to randomization~* Chronic pancreatitis or acute pancreatitis within 12 months of randomization~* Diagnosis of osteoporosis or currently taking bisphosphonates or teriparatide~* Diagnosis of an autoimmune connective tissue disorder (e.g., lupus erythematosus, scleroderma)~* Active gastroesophageal reflux disease \[GERD\] uncontrolled with a Proton Pump Inhibitor (PPI)~* Thyroid disease unless controlled with medication~* Currently taking Non-Steroidal Anti-Inflammatory Drugs \[NSAIDs\] (e.g., aspirin, ibuprofen, etc.) within 10 days prior to randomization and/or there is a need or expected use of these agents during the trial 12 months post index procedure~* Currently taking prescription antithrombotic therapy (e.g., anticoagulant or antiplatelet agent) within 10 days prior to randomization and/or there is a need or expected need to use during the trial 12 months post index procedure~* Currently taking systemic corticosteroids, drugs known to affect GI motility, prescription/over-the-counter weight loss medications, or medications known to cause significant weight gain or weight loss within 30 days prior to randomization and/or there is a need or expected need to use these medications during the trial 12 months post index procedure~* Medication for type 2 diabetes other than MET, SU, DPP-4i, and TZD (e.g., GLP1 or insulin) within 3 months of screening~* Chronic use of narcotics, opiates, benzodiazepines, or other addictive tranquilizers~* Allergy or hypersensitivity to ceftriaxone, cephalosporins, penicillin, or any equivalent antibiotics~* Active Helicobacter pylori infection (Note: Subjects may be eligible after undergoing 2 weeks of antibiotic treatment without re-screening)~* Previous GI surgery or abnormal GI anatomical finding that could preclude the ability to place the EndoBarrier device, liner or affect the function of the liner~* Abnormal pathologies or conditions of the gastrointestinal tract, including current ulcers or Crohn's disease, history of atresias or untreated stenoses, current upper gastrointestinal bleeding conditions within 3 months of randomization~* Any condition or major illness that places the subject at undue risk by participating in the study~* Poor dentition not allowing complete chewing of food~* Enrolled in another investigational study within 3 months of screening for this study (Enrollment in observational studies is permitted)~* Residing in a location without ready access to study site medical resources~* Documented weight loss of \>10 pounds anytime during the 3 months preceding randomization~* Positive stool guaiac at time of screening

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Device (EndoBarrier) (Type: EXPERIMENTAL): Device for glycemic control
- Sham Procedure (Type: SHAM_COMPARATOR): sham procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility